$36 Million Into a CRISPR Bet, Three Insiders Deep
Behzad Aghazadeh just committed $36,259,761 to Scribe Therapeutics at $15.16, and he's not alone. Three insiders have stepped in over the past 30 days, and he's a repeat buyer on top of that. This is a clinical-stage biotech with no revenue and a pipeline riding on CRISPR programs, so the risk is real and the technical read isn't there yet on a name this young. But cluster buying at this size, with capital that big at stake, is the kind of signal you don't ignore in a healthcare group that's holding up while the rest of the market rotates. Watch it closely and size accordingly.
The Filing
| Ticker | SCTX |
| Company | Scribe Therapeutics, Inc. |
| Insider | Behzad Aghazadeh |
| Buy amount | $36.3M |
| Filing date | July 28, 2026 |
| Conviction | Interesting · 54/100 |
| Setup type | Insufficient Data |
Ultimate members received this analysis in real time.